HK1256822A1 - 前列腺癌ncrna及其用途 - Google Patents

前列腺癌ncrna及其用途

Info

Publication number
HK1256822A1
HK1256822A1 HK18115907.0A HK18115907A HK1256822A1 HK 1256822 A1 HK1256822 A1 HK 1256822A1 HK 18115907 A HK18115907 A HK 18115907A HK 1256822 A1 HK1256822 A1 HK 1256822A1
Authority
HK
Hong Kong
Prior art keywords
ncrna
prostate cancer
prostate
cancer
cancer ncrna
Prior art date
Application number
HK18115907.0A
Other languages
English (en)
Inventor
Arul Chinnaiyan
John Prensner
Matthew Iyer
Original Assignee
Univ Michigan Regents
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Michigan Regents filed Critical Univ Michigan Regents
Publication of HK1256822A1 publication Critical patent/HK1256822A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HK18115907.0A 2010-11-19 2018-12-12 前列腺癌ncrna及其用途 HK1256822A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41549010P 2010-11-19 2010-11-19

Publications (1)

Publication Number Publication Date
HK1256822A1 true HK1256822A1 (zh) 2019-10-04

Family

ID=46084653

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18115907.0A HK1256822A1 (zh) 2010-11-19 2018-12-12 前列腺癌ncrna及其用途

Country Status (7)

Country Link
US (4) US20150284802A1 (zh)
EP (2) EP3336200A1 (zh)
CN (2) CN106434870A (zh)
AU (4) AU2011329753B2 (zh)
CA (2) CA2818486C (zh)
HK (1) HK1256822A1 (zh)
WO (1) WO2012068383A2 (zh)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8338109B2 (en) 2006-11-02 2012-12-25 Mayo Foundation For Medical Education And Research Predicting cancer outcome
EP2291553A4 (en) 2008-05-28 2011-12-14 Genomedx Biosciences Inc SYSTEMS AND METHODS FOR THE EXPRESSION-BASED DISTINCTION OF DIFFERENT CLINICAL ILLICIT STADIAS IN PROSTATE CANCER
US10407731B2 (en) 2008-05-30 2019-09-10 Mayo Foundation For Medical Education And Research Biomarker panels for predicting prostate cancer outcomes
US20130267443A1 (en) 2010-11-19 2013-10-10 The Regents Of The University Of Michigan ncRNA AND USES THEREOF
CN106434870A (zh) 2010-11-19 2017-02-22 密执安大学评议会 ncRNA及其用途
CA2858581A1 (en) 2011-12-13 2013-06-20 Genomedx Biosciences, Inc. Cancer diagnostics using non-coding transcripts
CA2881627A1 (en) 2012-08-16 2014-02-20 Genomedx Biosciences Inc. Cancer diagnostics using biomarkers
CN103146688B (zh) * 2012-09-12 2015-05-13 上海长海医院 长链非编码rna作为疾病诊断血液分子标志物的应用
WO2014152355A2 (en) * 2013-03-14 2014-09-25 The Broad Institute, Inc. Osteosarcoma-associated risk markers and uses thereof
WO2014205555A1 (en) * 2013-06-28 2014-12-31 British Columbia Cancer Agency Branch Methods and uses for diagnosis and treatment of prostate cancer
CA2940192C (en) 2014-02-04 2022-09-27 Thomas Jefferson University Specific expression of half-trna in cancers
WO2016087430A1 (en) * 2014-12-01 2016-06-09 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Novel RNA-biomarker signature for diagnosis of prostate cancer
CN105936904B (zh) * 2015-06-04 2018-07-20 佛山市第一人民医院 lncRNA分子ENST00000438553及其在鼻咽癌辅助诊断中的应用
CN106047876B (zh) * 2015-06-04 2018-11-02 佛山市第一人民医院 一种鼻咽癌相关分子标志物及其应用
CN106047875B (zh) * 2015-06-04 2018-11-02 佛山市第一人民医院 lncRNA分子及其在鼻咽癌辅助诊断中的应用
EP3390661B1 (en) * 2015-12-17 2022-05-04 Institut Curie Use of antisense long non-coding rnas for the diagnosis of prostate cancer
JP2019528758A (ja) * 2016-06-08 2019-10-17 エムアイアール サイエンティフィック，エルエルシー 前立腺癌の診断および治療のための方法および組成物
EP3504348B1 (en) 2016-08-24 2022-12-14 Decipher Biosciences, Inc. Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapy
US11208697B2 (en) 2017-01-20 2021-12-28 Decipher Biosciences, Inc. Molecular subtyping, prognosis, and treatment of bladder cancer
WO2018165600A1 (en) 2017-03-09 2018-09-13 Genomedx Biosciences, Inc. Subtyping prostate cancer to predict response to hormone therapy
AU2018266733A1 (en) 2017-05-12 2020-01-16 Veracyte, Inc. Genetic signatures to predict prostate cancer metastasis and identify tumor aggressiveness
CN107729719B (zh) * 2017-09-30 2020-05-26 中国科学院计算技术研究所 一种从头测序方法
CA3082391A1 (en) * 2017-11-12 2019-05-16 The Regents Of The University Of California Non-coding rna for detection of cancer
CN108998531B (zh) * 2018-08-31 2021-10-01 昆明医科大学第一附属医院 肺癌下调长链非编码rna标志物及其应用
CN108998530B (zh) * 2018-08-31 2021-10-08 昆明医科大学第一附属医院 肺癌上调长链非编码rna标志物及其应用
WO2023152568A2 (en) * 2022-02-10 2023-08-17 Oslo Universitetssykehus Hf Compositions and methods for characterizing lung cancer
CN114480651B (zh) * 2022-02-14 2023-10-20 天津市泌尿外科研究所 Pcat1的反义寡核苷酸及其在制备抑制前列腺癌核酸药物中的应用

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4323546A (en) 1978-05-22 1982-04-06 Nuc Med Inc. Method and composition for cancer detection in humans
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
DE3785591T2 (de) 1986-01-10 1993-09-02 Amoco Corp Kompetitiver homogener test.
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US5283174A (en) 1987-09-21 1994-02-01 Gen-Probe, Incorporated Homogenous protection assay
US5130238A (en) 1988-06-24 1992-07-14 Cangene Corporation Enhanced nucleic acid amplification process
US5225326A (en) 1988-08-31 1993-07-06 Research Development Foundation One step in situ hybridization assay
KR100242252B1 (ko) 1989-07-11 2000-03-02 다니엘 엘. 캐시앙 핵산서열의 증폭방법
CA2020958C (en) 1989-07-11 2005-01-11 Daniel L. Kacian Nucleic acid sequence amplification methods
US5455166A (en) 1991-01-31 1995-10-03 Becton, Dickinson And Company Strand displacement amplification
US5270184A (en) 1991-11-19 1993-12-14 Becton, Dickinson And Company Nucleic acid target generation
US5545524A (en) 1991-12-04 1996-08-13 The Regents Of The University Of Michigan Compositions and methods for chromosome region-specific probes
US5925517A (en) 1993-11-12 1999-07-20 The Public Health Research Institute Of The City Of New York, Inc. Detectably labeled dual conformation oligonucleotide probes, assays and kits
US5648211A (en) 1994-04-18 1997-07-15 Becton, Dickinson And Company Strand displacement amplification using thermophilic enzymes
JP3189000B2 (ja) 1994-12-01 2001-07-16 東ソー株式会社 特定核酸配列の検出方法
US5710029A (en) 1995-06-07 1998-01-20 Gen-Probe Incorporated Methods for determining pre-amplification levels of a nucleic acid target sequence from post-amplification levels of product
US5854206A (en) 1995-08-25 1998-12-29 Corixa Corporation Compounds and methods for treatment and diagnosis of prostate cancer
US6121489A (en) 1996-03-05 2000-09-19 Trega Biosciences, Inc. Selectively N-alkylated peptidomimetic combinatorial libraries and compounds therein
KR19990087802A (ko) 1996-03-15 1999-12-27 길리스 스티브 전립선암의 면역치료 및 면역진단을 위한 화합물 및 방법
DE69738687D1 (de) 1996-04-12 2008-06-26 Phri Properties Inc Sonden, kits und assays
US20030185830A1 (en) 1997-02-25 2003-10-02 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
PL196260B1 (pl) 1997-02-25 2007-12-31 Corixa Corp Polipeptyd, cząsteczka DNA, komórka gospodarza, białko fuzyjne, kompozycje farmaceutyczne i szczepionki do leczenia raka prostaty
AU6449398A (en) 1997-03-07 1998-09-22 Clare Chemical Research Llc Fluorometric detection using visible light
ES2402947T3 (es) * 1997-04-10 2013-05-10 Stichting Katholieke Universiteit University Medical Centre Nijmegen PCA3, genes PCA3 y métodos de uso
ATE440963T1 (de) 1998-07-02 2009-09-15 Gen Probe Inc Molekulare fackeln
US6573043B1 (en) 1998-10-07 2003-06-03 Genentech, Inc. Tissue analysis and kits therefor
US6828429B1 (en) 1999-03-26 2004-12-07 Henry M. Jackson Foundation For The Advancement Of Military Medicine Prostate-specific gene, PCGEM1, and the methods of using PCGEM1 to detect, treat, and prevent prostate cancer
US6303305B1 (en) 1999-03-30 2001-10-16 Roche Diagnostics, Gmbh Method for quantification of an analyte
EP1055734B1 (en) 1999-05-24 2004-10-13 Tosoh Corporation Method for assaying ribonucleic acid
AU2001245619A1 (en) * 2000-03-09 2001-09-17 Chiron Corporation Human genes and gene expression products
US7229774B2 (en) 2001-08-02 2007-06-12 Regents Of The University Of Michigan Expression profile of prostate cancer
US7507528B2 (en) 2001-09-06 2009-03-24 Adnagen Ag Method and diagnosis kit for selecting and or qualitative and/or quantitative detection of cells
JP4646315B2 (ja) * 2001-12-07 2011-03-09 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 前立腺癌においてアップレギュレートされた内因性レトロウイルス
CA2524572C (en) 2003-05-01 2018-07-10 Gen-Probe Incorporated Oligonucleotides comprising a molecular switch having enhanced sensitivity to the presence of a mismatch
US20050118625A1 (en) * 2003-10-02 2005-06-02 Mounts William M. Nucleic acid arrays for detecting gene expression associated with human osteoarthritis and human proteases
CA2898814C (en) 2004-08-27 2015-12-29 Gen-Probe Incorporated Single-primer nucleic acid amplification methods
US9957569B2 (en) * 2005-09-12 2018-05-01 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
US20070172841A1 (en) * 2006-01-25 2007-07-26 Hui Wang Probe/target stabilization with add-in oligo
US20080076674A1 (en) * 2006-07-06 2008-03-27 Thomas Litman Novel oligonucleotide compositions and probe sequences useful for detection and analysis of non coding RNAs associated with cancer
WO2008086478A2 (en) * 2007-01-10 2008-07-17 Henry Ford Health System Methods and compositions for identification of prostate cancer markers
CN103866008B (zh) * 2007-08-03 2016-06-29 俄亥俄州立大学研究基金会 编码ncrna的超保守区域
US20130267443A1 (en) 2010-11-19 2013-10-10 The Regents Of The University Of Michigan ncRNA AND USES THEREOF
CN106434870A (zh) 2010-11-19 2017-02-22 密执安大学评议会 ncRNA及其用途

Also Published As

Publication number Publication date
CN103403181B (zh) 2016-09-07
EP3336200A1 (en) 2018-06-20
CA2818486A1 (en) 2012-05-24
US20230016456A1 (en) 2023-01-19
CA3012765A1 (en) 2012-05-24
US20160251729A1 (en) 2016-09-01
US20150284802A1 (en) 2015-10-08
EP2640854B1 (en) 2018-02-21
AU2011329753A1 (en) 2013-06-06
WO2012068383A3 (en) 2012-08-16
CA2818486C (en) 2018-09-11
AU2015242941B2 (en) 2017-12-21
US11390923B2 (en) 2022-07-19
AU2017276340A1 (en) 2018-01-18
CN106434870A (zh) 2017-02-22
CN103403181A (zh) 2013-11-20
EP2640854A4 (en) 2014-05-07
EP2640854A2 (en) 2013-09-25
WO2012068383A2 (en) 2012-05-24
AU2015242941A1 (en) 2015-10-29
AU2020201232A1 (en) 2020-03-12
AU2011329753B2 (en) 2015-07-23
US20200165682A1 (en) 2020-05-28

Similar Documents

Publication Publication Date Title
HK1256822A1 (zh) 前列腺癌ncrna及其用途
SG10201710447QA (en) Pancreatic cancer biomarkers and uses thereof
IL225545A0 (en) Antibodies specific to cancerous tumors and their uses
IL223295A0 (en) Lung cancer biomarkers and uses thereof
ZA201207574B (en) Phytocannabinoids in the treatment of cancer
GB201016139D0 (en) Cancer phosholipidome
ZA201205806B (en) Phospholipid profiling and cancer
EP2625292A4 (en) KREBSBIOMARKER
EP2551956A4 (en) ANTENNA AND INTEGRATED ANTENNA
EP2550631A4 (en) MOBILE PAYMENTS
IL255309A0 (en) Reprogramming of cancer cells
SG10201500124VA (en) Methods and Compositions for Treating Cancer
EP2622091A4 (en) PEPTIDOMIMETICS OF COLON AND PANCREATIC CANCER
IL222958A0 (en) Cancer treatment
EP2457092A4 (en) CANCER BIOMARKERS AND THEIR USE
EP2611943A4 (en) METHODS AND COMPOSITIONS FOR CORRELATION OF GENETIC MARKERS TO THE RISK OF CANCER OF PROSTATE
EP2617416A4 (en) MEANS TO INCREASE CANCER THERAPY
EP2585115A4 (en) ANTICANCER TREATMENT
EP2533806A4 (en) METHODS AND MATERIALS FOR TREATING CANCER
EP2582384A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER
EP2537031A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER
GB201718726D0 (en) Phytocannabinoids in the treatment of cancer
GB0910751D0 (en) Prostate cancer vaccine
GB201004304D0 (en) Biomarkers for prostate cancer
EP2558590A4 (en) PROGNOSTIC MARKERS AND PROCEDURE FOR PROSTATE CANCER